Gates Ventures

• CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI

  Collaborator, Recruiting, 28 people, 8 Oct 2026

Sources: clinicaltrials.gov

• Blood Biomarkers of Alzheimer's Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

  6 Oct 2026

• Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer’s disease PET imaging biomarkers

  25 Sept 2026

• Generalizable MRI normative modelling to detect age-inappropriate neurodegeneration

  12 Nov 2025

Sources: api.crossref.org

• Global Incidence of All-Cause Dementia: A Meta-Analysis

  Grants or research support, 12 Oct 2026

• More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

  Grants or research support, 1 Sept 2026

• A multiancestry polygenic risk score for Alzheimer's disease is associated with cognitive decline and neuropathological hallmarks in diverse populations

  Grants or research support, 27 Aug 2026

• Plasma proteomic Alzheimer's risk score: Biological age clock and pseudotime trajectory

  Consulting or advice, Board or leadership role, 1 Oct 2025

Sources: pubmed.ncbi.nlm.nih.gov